Why is the Paradigm share price surging 7% today?

The biopharmaceutical company is partnering with the National Football League's Alumni Health service.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Paradigm shares lift more than 7% to $1.125 on Wednesday
  • The company entered into a research partnership to inform NFL Alumni members about osteoarthritis (OA)
  • NFL Alumni Health will pass on information about Paradigm’s role in developing a treatment for pain and dysfunction associated with knee osteoarthritis

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is in the green on Wednesday following the company's latest announcement.

At the time of writing, the biopharmaceutical company's shares are fetching at $1.055 each, up 0.48%. Earlier in the session, the company's share price hit $1.125, a surge of more than 7%.

A man in full American NFL playing kit crouches over with his arms across his chest in a defensive stance against a dark background.

Image source: Getty Images

What did Paradigm announce?

According to this morning's announcement, Paradigm advised that it has entered into a corporate partnership with the US's National Football League Alumni Health (NFLAH).

Under the collaboration, NFL Alumni Association (NFLAA) members will be informed about osteoarthritis (OA) and current treatment options. Furthermore, information will be provided to interested participants about actively enrolling in OA clinical trials throughout the United States.

The NFL's Alumni Association has more than 10,000 members which consist of former NFL players, coaches, executives, spouses, cheerleaders, and associate members.

Paradigm is seeking to unlock the potential benefits of pentosan polysulfate sodium (PPS) for the treatment of musculoskeletal disorders.

Paradigm's leading drug candidate Zilosul is used to treat OA, a progressive disease that affects more than 240 million people globally.

The injectable PPS treatment has previously shown improvements in pain reduction, joint function, and the prevention of cartilage damaging joints.

It seems investors are excited about the company expanding its access program for the potential treatment of OA, sending the Paradigm share price higher.

Paradigm CEO Marco Polizzi commented:

Having followed the progress of the expanded access program participants and hearing first-hand the positive impact Zilosul has had on their lives, Paradigm is honoured to be able to continue to work with NFL Alumni members to inform them of the onset and progression of osteoarthritis and Paradigm's clinical progress through phase 3 as we strive to bring Zilosul to commercialisation for the millions suffering from the debilitating effects of OA.

About the Paradigm share price

The Paradigm share price is down 48% in the past 12 months with most of these losses in the year to date.

The company's shares reached a 52-week low of 85.5 cents a share in late June before rebounding over the past two weeks.

Based on the current share price, Paradigm has a market capitalisation of around $236 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Healthcare Shares

Is the worst over for CSL shares after this week's sell-off?

It may be too early to completely write off the biotech stock.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Why are Resmed shares lagging if the business keeps compounding?

Resmed shares have had a tough time of late. But investors looking to compound returns over the long-term may want…

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is this ASX 300 share crashing over 20% today?

It is a very red day for this healthcare stock. What's happening? Let's find out.

Read more »

Six smiling health workers pose for a selfie.
Broker Notes

3 reasons this beaten down ASX All Ords healthcare share could come roaring back

A leading analyst believes this beaten down ASX healthcare stock is well-positioned for a comeback.

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Healthcare Shares

Down 59%: Will CSL shares ever regain momentum?

Here's what to expect over the next 12 months.

Read more »

A woman sits in front of a computer and does some calculations.
Healthcare Shares

Should you buy ResMed shares at their 52-week low?

This company is still growing, profitable, and exposed to a large sleep health market, but the share price has fallen…

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Healthcare Shares

How low can CSL shares go?

CSL shares have fallen 44% this year. Can they fall further?

Read more »

woman in lab coat conducting testing.
Healthcare Shares

3 reasons why this ASX biotech stock could double in value

Growing revenue and broker optimism are boosting confidence.

Read more »